

ELITE PHARMACEUTICALS INC /DE/
Form 3
December 20, 2006

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Subramanian Veerappan
 (Last) (First) (Middle)
 2. Date of Event Requiring Statement
 (Month/Day/Year)
 12/06/2006
 3. Issuer Name and Ticker or Trading Symbol
 ELITE PHARMACEUTICALS INC /DE/ [ELI]
 4. Relationship of Reporting Person(s) to Issuer
 5. If Amendment, Date Original Filed(Month/Day/Year)

C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE

(Street)

NORTHVALE, NJ 07647

(City) (State) (Zip)

(Check all applicable)

Director 10% Owner
 Officer Other
 (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	26,800	D	À
Common Stock	957,396	I	By VGS Pharma, LLC ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Warrants	12/06/2006	12/06/2011	Common Stock	478,698	\$ 3	I	By VGS Pharma, LLC ⁽²⁾
Stock Options	12/06/2006	12/06/2016	Common Stock	250,000	\$ 2.13	D	^
Stock Options	05/06/2007	12/06/2016	Common Stock	250,000	\$ 2.13	D	^
Stock Options	12/06/2007	12/06/2016	Common Stock	250,000	\$ 2.13	D	^
Stock Options	^ ⁽³⁾	12/06/2016	Common Stock	1,000,000	\$ 2.13	D	^

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Subramanian Veerappan C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE NORTHVALE, NJ 07647	^ X	^	^	^

Signatures

/s/ Veerappan
Subramanian

12/20/2006

**Signature of Reporting
Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Owned by VGS Pharma, LLC ("VGS"), a wholly-owned subsidiary of Kali Capital, L.P., which is controlled by Kali Management, LLC ("Kali"), its general partner, and Kali is controlled by the daughter of the Reporting Person, its managing member. The Reporting Person disclaims beneficial ownership of these shares of Common Stock, except to the extent of his pecuniary interest therein, if any.

(2) The Warrant is owned by VGS. See footnote no. 1. The Reporting Person disclaims beneficial ownership of the Warrant and the underlying shares of Common Stock, except to the extent of his pecuniary interest therein, if any.

(3) The vesting of these Stock Options shall depend upon the accomplishment of certain milestones with respect to the first or second drug product developed by the Issuer on or after February 4, 2007 under a certain Advisory Agreement, dated December 6, 2006, between the Issuer and the Reporting Person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.